KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Convertible Debt: 2013-2021

Historic Convertible Debt for Supernus Pharmaceuticals (SUPN) over the last 8 years, with Dec 2021 value amounting to $379.3 million.

  • Supernus Pharmaceuticals' Convertible Debt rose 9.38% to $400.4 million in Q1 2022 from the same period last year, while for Mar 2022 it was $400.4 million, marking a year-over-year increase of 9.38%. This contributed to the annual value of $379.3 million for FY2021, which is 4.84% up from last year.
  • Supernus Pharmaceuticals' Convertible Debt amounted to $379.3 million in FY2021, which was up 4.84% from $361.8 million recorded in FY2020.
  • Supernus Pharmaceuticals' 5-year Convertible Debt high stood at $379.3 million for FY2021, and its period low was $329.5 million during FY2018.
  • Moreover, its 3-year median value for Convertible Debt was $361.8 million (2020), whereas its average is $362.1 million.
  • Data for Supernus Pharmaceuticals' Convertible Debt shows a peak YoY grew of 4.84% (in 2021) over the last 5 years.
  • Supernus Pharmaceuticals' Convertible Debt (Yearly) stood at $329.5 million in 2018, then rose by 4.77% to $345.2 million in 2019, then grew by 4.80% to $361.8 million in 2020, then climbed by 4.84% to $379.3 million in 2021.